Company intelligence / Profile preview

Elios Vision

Ownership: Private
Development stage: Commercial

Overview

Elios Vision developed the first clinically validated, implant-free minimally invasive glaucoma surgery using an excimer laser. The ELIOS procedure is CE-marked and marketed in Europe with demonstrated efficacy and safety. A pivotal US clinical trial with over 300 patients was completed to support FDA approval. The company was acquired by Bausch + Lomb in December 2024 to expand global access to this innovative treatment.

Therapeutic areas: Ophthalmology
Modalities: DeviceLaser-based therapy
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

ELIOS

Commercial

Indications: Glaucoma, Ocular hypertension

Partnerships

Bausch + Lomb (acquirer/partner for commercialization)

Beyond the preview

Go deeper on Elios Vision.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elios Vision.

Explore the full profile